Skip to content

HR-EEG Contribution in Prognostic Evaluation of Language Development in Children With ASD

High Resolution Electroencephalogram Contribution in Prognostic Evaluation of Language Development in Children With Autism Spectrum Disorder

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05586672
Acronym
EE-TSA-LANG
Enrollment
120
Registered
2022-10-19
Start date
2023-01-02
Completion date
2028-06-30
Last updated
2022-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder, Child Language, Language Development, Neurocognitive Disorders

Keywords

High Resolution electroencephalogram, Child, Autism Spectrum Disorder, Language

Brief summary

The goal of this prospective observational multicentric cohort study is to evaluate the clinical prognostic value of the speech tracking score of language development in children with ASD aged from 3 years to 4 years and half at inclusion. Participants will followed during 4 years with an annual visit. During these visits, each participant will be clinically evaluated (scales and tests) and performed an EEG-HR recording. Two groups will be formed, one with children diagnosed with ASD with language delay, and a control group composed of non-ASD children without language delay, matched on age and gender with the ASD group.

Detailed description

Two groups will be formed, one with children diagnosed with ASD with language delay, and a control group composed of non-ASD children without language delay, matched on age and gender with the ASD group. \- ASD group : For children in the ASD group, 4 visits were planned (inclusion visit, then at one year, two years and three years). During study visit, each child will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks (modulated pure tones, synthetic voice, recorded voice, real voice, with congruent and non-congruent pictorial supports). \- Control group : For children in the control group, 1 visit was planned : data will be collected at the inclusion visit only. During this visit, each child will be clinically evaluated with standardized scales and tests and will performed an EEG-HR recording while listening to successive soundtracks (modulated pure tones, synthetic voice, recorded voice, real voice, with congruent and non-congruent pictorial supports).

Interventions

DEVICEEEG-HR

Passation EEG-HR

DIAGNOSTIC_TESTADI-R

Passation of ADI-R scale

DIAGNOSTIC_TESTADOS-2

Passation of ADOS-2 scale

DIAGNOSTIC_TESTIDE

Passation of IDE scale

DIAGNOSTIC_TESTMSEL

Passation of MSEL scale

DIAGNOSTIC_TESTDunn

Passation of Dunn scale

Sponsors

Etablissement Public de Santé Barthélemy Durand
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
3 Years to 4 Years
Healthy volunteers
Yes

Inclusion criteria

For all participants * Child aged from 3 years to 4 years and half at inclusion. * Information delivered and no parental objection for study participation. For ASD group * Diagnosis of ASD according to DSM-V criteria. * Expressive language level \< 27 months regarding on IDE scale. For Control group - Matched on age (at +/- 3 months) and gender to ASD group participants.

Exclusion criteria

For all participants * Any illness or treatment that could significantly alter EEG-HR recording (epilepsy, anti-epileptic treatment, psychotropic drugs...). * Major hearing or vision disorders. For ASD group \- Severe and characterised neurological pathology other than ASD For Control group * Characterised neurological or psychiatric pathology. * Characteristic language delay.

Design outcomes

Primary

MeasureTime frameDescription
Ability to discriminate children language development4 yearsThe primary endpoint is the ability to discriminate children whose language development will be favourable (developmental level ≥ 27 months) from those whose language development will be unfavourable (\< 27 months) based on the speech tracking measure (on the EEG-HR at inclusion).

Secondary

MeasureTime frameDescription
Comparison of speech tracking scores4 yearsComparison of speech tracking scores (phases 1 to 3 of the HR EEG recording protocol).
Evolution of the predictive model4 yearsEvolution of the predictive model by integrating data: clinical, longitudinal evolution of speech tracking, deviation from the mean of the control group speech tracking and evolution of speech tracking.
Measures of association by synchronous and diachronic analyses4 yearsMeasures of association by synchronous and diachronic analyses (mixed generalized linear models for repeated measures).

Countries

France

Contacts

Primary ContactAdelaide Aduayi
adelaide.aduayi@eps-etampes.fr+33 1 75 02 16 81
Backup ContactMorgane Da Silva Hennequin
morgane.dasilvahennequin@eps-etampes.fr+33 1 82 26 81 08

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026